written on 11.04.2014

Natco looking to block Indian patent for Gilead's Sovaldi

TAGS: ,

India may now be taking compulsory licensing one step further, with domestic Natco Pharma asking the country's patent office to deny Gilead Sciences protection on its brand-new hep C treatment in the first place.